Part 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injections
- 1ChromaDex, Inc., a Niagen Bioscience, Inc., company
Abstract
Nicotinamide riboside (NR), an endogenous precursor to the essential coenzyme nicotinamide adenine dinucleotide (NAD+), is characterized as safe and effective for longitudinally elevating NAD+ in blood and tissues, when administered orally. Interest in alternative routes of administration of NR has increased in recent years and led to the development of pharmaceutical-grade NR for intravenous and injectable administration. To evaluate the safety and efficacy of repeat daily injections of NR, an open-label, pilot, trial was initiated. Utilizing a 2x2 parallel study design, 39 study participants were randomized to intramuscular (IM) or subcutaneous (SC) injection administration, and 50 or 100 mg of NR, for 3 consecutive days, followed by a 7-day washout (50 mg IM, n=7; 100 mg IM, n=11; 50 mg SC, n=11; and 100 mg SC, n=10). To assess the primary outcome of safety, vitals, blood biomarkers, and adverse event monitoring were employed. Additional assessments included NAD+ pharmacokinetics and subjective participant-reported outcomes. Daily injections of NR were well tolerated and did not result in any unexpected adverse events or experiences. Pain and muscle soreness/tightness more than two minutes after the injection were reported by 44% and 41% of the participants, respectively, regardless of the route of administration or dose. Significant heterogeneity of pharmacokinetic parameters for NAD+ augmentation of whole blood was observed, however an average of the daily percentage increases in NAD+ was consistent across treatment groups, resulting in 9.51, 9.97, 7.83, and 9.05% for 50 mg IM, 100 mg IM, 50 mg SC, and 100 mg SC, respectively. Exploratory participant-reported outcomes suggest potential benefits on fatigue and sleep, with mixed effects on global physical health. Repeat daily injections of NR were well tolerated, and findings warrant investigation in larger, powered, placebo-controlled trials.
Significance StatementInjected nicotinamide riboside (NR) was well tolerated in the study population and did not result in any treatment group safety signals. The injections increased whole blood NAD+, but the variability of timing and extent of such increase varied with each individual. The use of participant-reported outcomes suggests potential perceived benefits for fatigue, sleep, and global physical health, which require further evaluation in larger studies with a placebo control to conclude benefits in these areas.
Related
- Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections
- Outcomes and prognostic factors in dogs with subcutaneous and intramuscular hemangiosarcoma treated with hypofractionated radiation therapy and chemotherapy.
- Comparison of subcutaneous and intravenous administration of the monoclonal antibody CSX-1004 on fentanyl-induced respiratory depression in squirrel monkeys
- Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain
- Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures
BibTeX
@misc{nkrumahelie2026part,
title = {{Part 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injections}},
author = {Y. Nkrumah-Elie and J. Kwon and A. Russ and S. Sampson and F. Hailu and T. Allen and H. Chen and A. Shao},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.26365345},
url = {https://www.medrxiv.org/content/10.64898/2026.10.12.26365345v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Part 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injections
AU - Y. Nkrumah-Elie
AU - J. Kwon
AU - A. Russ
AU - S. Sampson
AU - F. Hailu
AU - T. Allen
AU - H. Chen
AU - A. Shao
PY - 2026
DA - 2026/10/12
PB - medRxiv
DO - 10.64898/2026.10.12.26365345
UR - https://www.medrxiv.org/content/10.64898/2026.10.12.26365345v1
AB - Nicotinamide riboside (NR), an endogenous precursor to the essential coenzyme nicotinamide adenine dinucleotide (NAD+), is characterized as safe and effective for longitudinally elevating NAD+ in blood and tissues, when administered orally. Interest in alternative routes of administration of NR has increased in recent years and led to the development of pharmaceutical-grade NR for intravenous and injectable administration. To evaluate the safety and efficacy of repeat daily injections of NR, an open-label, pilot, trial was initiated. Utilizing a 2x2 parallel study design, 39 study participants were randomized to intramuscular (IM) or subcutaneous (SC) injection administration, and 50 or 100 mg of NR, for 3 consecutive days, followed by a 7-day washout (50 mg IM, n=7; 100 mg IM, n=11; 50 mg SC, n=11; and 100 mg SC, n=10). To assess the primary outcome of safety, vitals, blood biomarkers, and adverse event monitoring were employed. Additional assessments included NAD+ pharmacokinetics and subjective participant-reported outcomes. Daily injections of NR were well tolerated and did not result in any unexpected adverse events or experiences. Pain and muscle soreness/tightness more than two minutes after the injection were reported by 44% and 41% of the participants, respectively, regardless of the route of administration or dose. Significant heterogeneity of pharmacokinetic parameters for NAD+ augmentation of whole blood was observed, however an average of the daily percentage increases in NAD+ was consistent across treatment groups, resulting in 9.51, 9.97, 7.83, and 9.05% for 50 mg IM, 100 mg IM, 50 mg SC, and 100 mg SC, respectively. Exploratory participant-reported outcomes suggest potential benefits on fatigue and sleep, with mixed effects on global physical health. Repeat daily injections of NR were well tolerated, and findings warrant investigation in larger, powered, placebo-controlled trials. Significance StatementInjected nicotinamide riboside (NR) was well tolerated in the study population and did not result in any treatment group safety signals. The injections increased whole blood NAD+, but the variability of timing and extent of such increase varied with each individual. The use of participant-reported outcomes suggests potential perceived benefits for fatigue, sleep, and global physical health, which require further evaluation in larger studies with a placebo control to conclude benefits in these areas.
ER -